Q4 2021 Results

Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Innovation: Pipeline overview Appendix Innovation: Clinical trials Net debt significantly decreased by USD 23.6bn driven by proceeds from Roche divestment and strong FCF (USD bn) +23.6 20.7 0.6 -0.9 -24.5 -7.4 -0.6 -3.0 Dec 31, 2020 Dividends M&A transactions Treasury share transactions, 13.3 Free Cash Flow net Proceeds from Roche divestment Others Dec 31, 2021 53 Investor Relations | Q4 2021 Results U NOVARTIS | Reimagining Medicine

View entire presentation